Nursing hbrp Domain
Published February 6, 2026 | Version v1
Journal article Open

An Indispensible Parameters of Dilated Cardio Myopathy Include Etiology Include Etiology, Epidemiology, Patho Physiology, Diagnosis, Differential Diagnosis, Treatment, Prognosis, Complications and Health Care Outcomes

Authors/Creators

Description

Dilated Cardiomyopathy (DCM) is a disease of heart muscle manifested by enlargement and dilation of one or both of the ventricles along with impaired contractility narrated as left ventricular ejection fraction (LVEF) less than 40%. Patients may or may not have overt signs of heart failure, but they are by definition exhibiting systolic dysfunction. There are two types of DCM for this disease process: primary and secondary. Since primary DCM is thought to be idiopathic, secondary causes must be ruled out before the diagnosis can be made. This exercise describes the causes, symptoms, and importance of the interprofessional team in managing dilated cardiomyopathy.

Files

An Indispensible Parameters of Dilated Cardio Myopathy -Formatted Paper.pdf

Files (434.3 kB)

Additional details

References

  • 1. Hershberger, R. E., & Jordan, E. (2007, July 27). Dilated cardiomyopathy overview. In M. P. Adam, J. Feldman, G. M. Mirzaa, R. A. Pagon, S. E. Wallace, A. Amemiya, et al. (Eds.), GeneReviews® [Internet]. University of Washington, Seattle. https://www.ncbi.nlm.nih.gov/books/NBK1309/
  • 2. Stergiopoulos, K., & Lima, F. V. (2019). Peripartum cardiomyopathy—Diagnosis, management, and long-term implications. Trends in Cardiovascular Medicine, 29(3), 164–173. https://doi.org/10.1016/j.tcm.2018.07.007
  • 3. Paldino, A., De Angelis, G., Merlo, M., Gigli, M., Dal Ferro, M., Severini, G. M., Mestroni, L., & Sinagra, G. (2018). Genetics of dilated cardiomyopathy: Clinical implications. Current Cardiology Reports, 20(10), 83. https://doi.org/10.1007/s11886-018-1036-0
  • 4. Vikhorev, P. G., & Vikhoreva, N. N. (2018). Cardiomyopathies and related changes in contractility of human heart muscle. International Journal of Molecular Sciences, 19(8), 2415. https://doi.org/10.3390/ijms19082415
  • 5. Masarone, D., Kaski, J. P., Pacileo, G., Elliott, P. M., Bossone, E., Day, S. M., & Limongelli, G. (2018). Epidemiology and clinical aspects of genetic cardiomyopathies. Heart Failure Clinics, 14(2), 119–128. https://doi.org/10.1016/j.hfc.2017.11.003
  • 6. Bakalakos, A., Ritsatos, K., & Anastasakis, A. (2018). Current perspectives on the diagnosis and management of dilated cardiomyopathy beyond heart failure: A Cardiomyopathy Clinic doctor's point of view. Hellenic Journal of Cardiology, 59(5), 254–261. https://doi.org/10.1016/j.hjc.2018.02.005
  • 7. Palomer, X., Pizarro-Delgado, J., & Vázquez-Carrera, M. (2018). Emerging actors in diabetic cardiomyopathy: Heartbreaker biomarkers or therapeutic targets? Trends in Pharmacological Sciences, 39(5), 452–467. https://doi.org/10.1016/j.tips.2018.02.007
  • 8. Dainis, A. M., & Ashley, E. A. (2018). Cardiovascular precision medicine in the genomics era. JACC: Basic to Translational Science, 3(2), 313–326. https://doi.org/10.1016/j.jacbts.2018.01.002
  • 9. Mu, M., Majoni, S. W., Iyngkaran, P., Haste, M., & Kangaharan, N. (2019). Adherence to treatment guidelines in heart failure patients in the Top End region of Northern Territory. Heart, Lung and Circulation, 28(7), 1042–1049. https://doi.org/10.1016/j.hlc.2018.05.211
  • 10. Bertini, M., Balla, C., Pavasini, R., & Boriani, G. (2018). Efficacy of cardiac resynchronization therapy in patients with isolated ventricular noncompaction with dilated cardiomyopathy: A systematic review of the literature. Journal of Cardiovascular Medicine (Hagerstown), 19(7), 324–328. https://doi.org/10.2459/JCM.0000000000000663